Biotech Values

[BiotechValues]

Agree completely on transparency of course.

re: SRNE- I think it's not only a big investment from Soon-Shiong that's got people's attention, it's the fact that this was described as an "initial" investment, and his privately-held company, Natworks and Sorrento will be launching a JV.

He's a bit of a showman of course, but he did develop Abraxane and sold it to Celgene for $2.9 billion as many know.

Despite the recent bump on SRNE shares, market cap is small at $350 million- compared to JUNO's $4.1 billion. With the JV launch next year, I think SRNE could be an easy double and would buy it before JUNO for example at current prices. Based on today's share price action in JUNO vs. SRNE, I'd say I'm not alone.